The purchase of the privately held ratiopharm Group solidifies Teva's number one position in the European generics industry and fits well with its goal of expanding the gap between itself and competitors. Importantly, it gives Teva a firm standing in Germany, where it had been a minor player.
Teva Pharmaceutical Industries Ltd.'s acquisition of ratiopharm Group, the German generics company, announced March 18, could hardly have been a surprise for anyone following the Israeli company's recent rip-roaring endorsement of the opportunities in the European generics market and the German market in particular. [See Deal]
The purchase of the privately held ratiopharm Group solidifies Teva's number one position in the European generics industry and fits...
In the latest episode of the In Vivo Podcast, Jeremy Skillington, CEO of Poolbeg Pharma, discussed the company’s ambitious pipeline and strategic direction.
Lonza is addressing the growing global demand for biologics by utilizing its expert teams and the advanced capabilities of its newly acquired large-scale manufacturing site in Vacaville, California. Joanna McCafferty, Director of Commercial Development, shares more in this brief video. Ask ChatG
Understand who’s influencing access decisions and how pharma can engage strategically across the continent.
